[{"orgOrder":0,"company":"BirchBioMed","sponsor":"Bionexus Gene Lab","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"DTXCID5040675","moa":"GPR35","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"BirchBioMed","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"BirchBioMed \/ BioNexus Gene Lab","highestDevelopmentStatusID":"9","companyTruncated":"BirchBioMed \/ BioNexus Gene Lab"}]

Find Clinical Drug Pipeline Developments & Deals for DTXCID5040675

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Florida Innovation
                          Not Confirmed
                          Florida Innovation
                          Not Confirmed

                          Details : The collaboration aims to advance the clinical development of Kynurenic Acid for targeting GPR35 in the treatment of organ fibrosis.

                          Product Name : FS-2

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          October 20, 2025

                          Lead Product(s) : DTXCID5040675

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Bionexus Gene Lab

                          Deal Size : $10.0 million

                          Deal Type : Collaboration

                          blank